Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

Axicabtagene ciloleucel (axi‐cel) is an autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed or refractory large B‐cell lymphoma (R/R LBCL). To reduce axi‐cel–related toxicity, several exploratory safety management cohorts were added to ZUMA‐1 (NCT02348216), the...

Descripción completa

Detalles Bibliográficos
Autores principales: Topp, Max S., van Meerten, Tom, Houot, Roch, Minnema, Monique C., Bouabdallah, Krimo, Lugtenburg, Pieternella J., Thieblemont, Catherine, Wermke, Martin, Song, Kevin W., Avivi, Irit, Kuruvilla, John, Dührsen, Ulrich, Zheng, Yan, Vardhanabhuti, Saran, Dong, Jinghui, Bot, Adrian, Rossi, John M., Plaks, Vicki, Sherman, Marika, Kim, Jenny J., Kerber, Anne, Kersten, Marie José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematological malignancy‐Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293158/
https://www.ncbi.nlm.nih.gov/pubmed/34590303
http://dx.doi.org/10.1111/bjh.17673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293158/
https://www.ncbi.nlm.nih.gov/pubmed/34590303
http://dx.doi.org/10.1111/bjh.17673

Ejemplares similares